home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Pulsed Drug Delivery From Polymers

  October, 21 2003 8:48
your information resource in human molecular genetics
Prescription drugs dominate many people’s lives, but the advent of controlled-release delivery systems is set to change all that. Examples already in the marketplace include time-release pills that reduce the number of doses required for pain relievers and antidepressants, and contraceptive patches and implants. In the November issue of Nature Materials, Robert Langer and colleagues report a novel polymer-based pulsed drug delivery system designed to release accurate doses of drugs from an implant at predetermined times.

The drug delivery system is based on a microchip formed from poly(L-lactic acid), which is a slowly degrading polyester. The drug solutions are injected into reservoirs on the chip surface, and sealed by biodegradable polymer membranes with different degradation rates. By varying the composition and molecular weight of each polymer membrane, Langer and colleagues are able to tightly control the degradation rate (and thus drug release time) over a wide range.

The new polymer-based system is capable of releasing a variety of different drugs at well-controlled times. So far, the researchers have demonstrated that heparin -- a common anticoagulant -- remains bioactive after incorporation and release from the system over periods up to 140 days. Given the high biocompatibility and superb performance of the polymer-based system, clinical demonstration should not be too far off.

Author contact:

Robert Langer
Massachusetts Institute of Technology
Cambridge, MA
Tel: +1 617 253 3107/3123
E-mail: rlanger@mit.edu

Also available online.

(C) Nature Materials press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.